Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes

Jan 14, 2020

Overview : Trial Reference Schüpke S, Neumann FJ, Menichelli M, et al.; ISAR-REACT 5 Trial Investigators. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019 Oct 17;381(16):1524-1534. doi: 10.1056/NEJMoa1908973. Abstract | Full Text Expert Comment Pablo Avanzas,... more

Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

Dec 18, 2019

Overview : Trial Reference Tardif JC, Kouz S, Waters DD, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Nov 16. doi: 10.1056/NEJMoa1912388. [Epub ahead of print] Abstract | Full Text Expert Comment Pablo Avanzas,... more

Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Jul 09, 2019

Overview : Trial Reference Manson JE, Cook NR, Lee IM, Christen W, VITAL Research Group. Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL). N Engl J Med. 2019 Jan 3;380(1):33-44. Abstract | Full Text   Expert Comment Ricardo Lopez Santi, ISCP Governor for Argentina... more

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia: The REDUCE-IT trial

Apr 01, 2019

Overview : Trial Reference Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380:11-22. Abstract | Full Text Expert Comment Maria Eliane Campos Magalhães and Andréa Araujo Brandão Background A long-standing association... more

Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors

Feb 28, 2019

Overview : Trial Reference Connolly SJ, Crowther M, Eikelboom JW, et al.; ANNEXA-4 Investigators. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019 Feb 7 [Epub ahead of print]. Abstract | Full Text   Expert... more

Intravenous Iron in Patients Undergoing Maintenance Hemodialysis: the PIVOTAL trial

Feb 14, 2019

Overview : Trial References Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, and Ford I, for the PIVOTAL Investigators and Committees. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.... more

Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure

Nov 14, 2018

Overview : Trial Reference Velazquez EJ, Morrow DA, DeVore AD, et al., for the PIONEER-HF Investigators. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2018 Nov 11 [epub ahead of print]. Abstract | Full Text   Expert Comment Pablo Avanzas. Professor of Medicine, Universidad de... more

Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness (MARINER)

Sep 13, 2018

Overview : Trial References Spyropoulos AC, Ageno W, Albers GW, et al.; MARINER Investigators. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1805090. Abstract | Full Text Expert Comment Pablo del Castillo Vazquez,  Antoni Martínez-Rubio: Department of Cardiology, University Hospital of... more

Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients (CAMELLIA–TIMI 61)

Sep 13, 2018

Overview : Trial References Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients - Thrombolysis in Myocardial Infarction 61 (CAMELLIA–TIMI 61) Expert Comment Amelia Carro. Hospital Universitario Vall d’Hebrón. Universidad Autónoma de Barcelona, Barcelona, Spain. Background Obesity is a major... more

Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE Trial)

Aug 27, 2018

Overview : Use of Aspirin to Reduce Risk of Initial Vascular Events in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE): A Randomised, Double-blind, Placebo-controlled Trial Trial Reference Gaziano JM, Brotons C, Coppolecchia R, et al. Use of Aspirin to Reduce Risk... more

Page: